11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy

• Published in: Pituitary Vol. 25; no. 4; pp. 573 - 586
• Main Authors: Bashari, W. A., van der Meulen, M., MacFarlane, J., Gillett, D., Senanayake, R., Serban, L., Powlson, A. S., Brooke, A. M., Scoffings, D. J., Jones, J., O’Donovan, D. G., Tysome, J., Santarius, T., Donnelly, N., Boros, I., Aigbirhio, F., Jefferies, S., Cheow, H. K., Mendichovszky, I. A., Kolias, A. G., Mannion, R., Koulouri, O., Gurnell, M.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.08.2022; Springer Nature B.V
• Subjects: Adenoma; Agonists; Decision making; Dopamine; Endocrinology; Functional magnetic resonance imaging; Human Physiology; Hyperprolactinemia; Intolerance; Localization; Magnetic resonance imaging; Medical treatment; Medicine; Medicine & Public Health; Methionine; Patients; Pituitary; Prolactin; Radiation therapy; Radiosurgery; Remission; Surgery; Tumors; C-methionine PET; Dopamine agonist intolerance/ resistance; Microprolactinoma

Purpose To assess the potential for 11 C-methionine PET (Met-PET) coregistered with volumetric magnetic resonance imaging (Met-PET/MR CR ) to inform clinical decision making in patients with poorly visualized or occult microprolactinomas and dopamine agonist intolerance or resistance. Patients and m...